1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)

BACKGROUND: In previous studies, patients switching from Tenofovir Disoproxil (TDF) to Long Acting Injectable (LAI) Cabotegravir/Rilpivirine demonstrated improvement in renal outcomes. Furthermore, Tenofovir Alafenamide (TAF) has shown improved renal outcomes compared TDF. In this study, we aim to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayala, Alvaro, McNaboe, Lukas, Kostka, Julia, Chirch, Lisa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677085/
http://dx.doi.org/10.1093/ofid/ofad500.1397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677085/
http://dx.doi.org/10.1093/ofid/ofad500.1397

Ejemplares similares